Synucure Therapeutics

Synucure Therapeutics Inc., a Canadian biotechnology company founded in 2021, focuses on developing treatments for brain degenerative disorders, particularly Parkinson's disease (PD). The company builds on the preclinical work of Dr. Francesca Cicchetti, utilizing a repurposed drug, Cysteamine, which has shown potential in preventing and reversing PD-related features in animal and cell models. Synucure aims to create a Disease Modifying Therapy (DMT) that could halt and potentially reverse PD progression. Additionally, the company is working on patented blood biomarkers to offer a simple blood test for more precise and rapid PD diagnosis, benefiting clinicians, patients, and the industry. Synucure's business model involves drug development and licensing agreements, such as the exclusive licensing with Laval for proprietary blood biomarkers. The company collaborates with experts to develop SYN 001, a novel Cysteamine formulation tailored to clinical needs. Synucure's mission is to become a leader in PD treatment and diagnosis, serving the healthcare sector with innovative solutions.

Keywords: biotechnology, Parkinson's, Cysteamine, biomarkers, diagnosis, treatment, drug development, licensing, healthcare, clinical.